he cardiac natriuretic peptides consist of B-type and atrial natriuretic peptides (BNP and ANP) and exert natriuretic and vasodilatory properties. 1 BNP is released mainly by the ventricle and ANP by the atrium in response to volume expansion, pressure overload, and the resultant increased wall stress. 2 Thus, measurement of plasma natriuretic peptide levels, particularly BNP levels, may be useful for the diagnosis of heart failure (HF) and detection of left ventricular (LV) dysfunction. [3] [4] [5] Furthermore, elevated BNP levels are associated with adverse prognosis in patients with HF 6-8 and those with coronary artery disease (CAD), 9,10 even in community-dwelling subjects. 11 In these populations, anemia also has emerged as a powerful predictor for adverse cardiovascular outcomes. [12] [13] [14] [15] Although several recent studies have reported an association between anemia and elevated plasma BNP levels in patients with HF, 16,17 those with CAD 18 and in normal subjects, 19 it is unknown whether the association is mediated by the hemodynamic effects of anemia, including reduced systemic vascular resistance, increased venous return and LV filling, and resultant increased cardiac output (CO), 20 and none of the studies reported for ANP. Accordingly, we examined the independent association of anemia with plasma BNP and ANP levels in patients undergoing cardiac catheterization for evaluation of CAD.
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Cardiac Catheterization
Right atrial and pulmonary capillary wedge pressures were obtained with a flow-directed pulmonary artery catheter. CO was measured by thermodilution and indexed to body surface area. Before contrast material was injected into the LV or coronary artery, LV and aortic pressure waves were obtained with a catheter-tipped micromanometer (SPC-454D, Millar Instrument Company, Houston, TX, USA) and recorded on both a polygraph system (RMC-2000, Nihon Kohden, Inc, Tokyo, Japan) and a digital data recorder (NR-2000, Keyence, Osaka, Japan) as previously reported. 21, 22 From the recorded pressure waves, the peak positive and negative first derivatives of LV pressure (dP/dt) were determined. A time constant of decrease in LV pressure ( ) was computed by applying a monoexponential fitting with zero asymptote to the LV pressure decay. 23 LV end-systolic and end-diastolic volumes were obtained from biplane left ventriculography using the method proposed by Chapman et al 24 and were used for calculating the ejection fraction. These volumes were corrected for body surface area. Systemic vascular resistance index was calculated as mean aortic pressure minus mean right atrial pressure divided by cardiac index.
Blood Sampling
Venous blood samples for the assay of plasma natriuretic peptide levels were collected from the right femoral vein at cardiac catheterization. The natriuretic peptide levels were measured with a specific immunoradiometric assay for human natriuretic peptides (Shionoria, Shionogi Co, Ltd, Osaka, Japan). The lowest detectable measurement for this assay was 4 pg/ml for BNP and 5 pg/ml for ANP. Within a week before the index cardiac catheterization for this study, complete blood count and blood chemistry were obtained for assessment of clinical features. Serum hemoglobin (Hb) levels were determined by a sodium lauryl sulfate method (XE-2100, Sysmex, Kobe, Japan). Serum creatinine levels were determined by an enzymatic assay method (Kainos CRE-L kit, Kainos, Tokyo, Japan). Anemia was defined as Hb levels <12 g/dl for females and <13 g/dl for males according to the World Health Organization criteria. Glomerular filtration rate was estimated by the Cockcroft-Gault formula. 25 
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Statistical Analysis
We used the SAS program package (SAS Institute, Cary, NC, USA) for all statistical analyses. Differences between groups were compared by Student's t-test for continuous variables and 2 test for categorical variables. The association between continuous variables was determined by Pearson's correlation analysis. Because natriuretic peptide values were not normally distributed, a logarithmic transformation was used. Linear and logistic regression was performed for a continuous and a dichotomous outcome, respectively. To determine the variables independently associated with natriuretic peptide levels, stepwise multivariate linear regression including all clinical and hemodynamic variables as candidates was performed with p= 0.05 for threshold for inclusion or exclusion of a variable. To determine the independent predictors for elevated (greater than third quartile value) natriuretic peptide levels, similar stepwise multivariate logistic regression was performed. To further assess the independent predictive value of anemia, multivariate logistic regression was performed by forcefully including clinical and hemodynamic variables that showed significant difference between patients with and without anemia. Risk for elevated natriuretic peptide levels is expressed as odds ratio (OR) with its 95% confidence interval (CI); p<0.05 was considered significant.
Results
Clinical Features
Clinical characteristics of all patients and the subgroups are shown in Table 1 . Patients without anemia, compared with those with anemia were more likely to be older with greater severity of CAD, to have lower body mass index and glomerular filtration rate, to be prescribed diuretics, and to have higher BNP and ANP levels.
Hemodynamic variables of all patients and subgroups are also shown in Table 1 . Compared with patients without anemia, those with anemia were more likely to have lower systemic vascular resistance index and higher heart rate, mean pulmonary capillary wedge pressure, and cardiac index.
Relationship Between Hb and Natriuretic Peptide Levels
Correlation coefficients of hemodynamic and clinical variables with natriuretic peptide levels are shown in Table 2 . An inverse correlation was observed between serum Hb and plasma levels of BNP and ANP (Fig 1) . When analyses were performed separately for males and females, Hb correlated significantly with BNP and ANP levels (correlation coefficients for BNP and ANP, -0.35 and -0.33, p<0.001 and p<0.001, respectively, for males; -0.52 and -0.27, p<0.001 and p<0.05, respectively, for females). Stepwise multivariate regression including as candidates all variables listed in Table 1 showed that Hb level was independently associated with BNP and ANP levels (Table 3) . Table 4 ). After forcefully including the clinical and hemodynamic variables that showed significant difference between patients with and without anemia, including age, body mass index, the severity of CAD, glomerular filtration rate, heart rate, mean pulmonary capillary wedge pressure, CO, and systemic vascular resistance index, into the models, the predictive value of anemia for elevated natriuretic peptide levels remained significant (adjusted OR 
Discussion
Major Findings
In the present study, we examined whether the association of anemia with elevated plasma levels of natriuretic peptides is mediated by the hemodynamic effects of anemia in patients undergoing cardiac catheterization for the evaluation of CAD. We observed that serum Hb correlated inversely with plasma BNP and ANP levels and that the correlation was independent of other cardiac and noncardiac determinants of natriuretic peptide levels, including LV end-diastolic pressure and body mass index. Anemia (serum Hb levels <12 g/dl for females; <13 g/dl for males) was a significant predictor for elevated BNP and ANP levels and the predictive value remained significant after adjustment for other predictors and differences in hemodynamic and clinical variables between patients with and without anemia, including glomerular filtration rate and the severity of CAD. Thus, we found that anemia is an independent predictor for elevated plasma natriuretic peptide levels in patients with known or suspected CAD.
Comparison With Earlier Studies
The present study has 2 novel findings. First, our study shows that the association of anemia with elevated BNP levels is independent of the hemodynamic changes caused by anemia. Furthermore, we proved that the association continues to be independent of the hemodynamic effects of anemia even after adjustment for hemodynamic determinants of elevated BNP levels, including increased LV volume and LV end-diastolic pressure and slow LV relaxation. Another novel finding of the present study is that anemia is independently associated with elevated ANP levels. To our knowledge, the present study is the first to show such an association.
Possible Mechanisms
Although the present study does not provide direct mechanisms underlying the association between anemia and elevated natriuretic peptide levels, there are possible explanations. In the presence of anemia, CO must be increased to compensate for the reduced oxygen-carrying capacity. This is accomplished by (1) a decrease in systemic vascular resistance because of the combination of a reduced blood viscosity and hypoxia-induced vasodilatation, (2) a resultant increase in venous return, and (3) the positive inotropic and chronotropic effects of increased sympathetic activity. 20 In addition, the activated renin -angiotensin system in the presence of anemia may play a role in the enhancement of CO by retaining salt and water and thus increasing venous return. 26 However, the activated sympathetic nervous and renin -angiotensin systems increase circulating vasoconstrictive neurohormones, including catecholamines and angiotensin II, and elevate systemic vascular resistance, thereby limiting their ability to enhance CO. Thus, the production of natriuretic peptides, which have a potent vasodilatory property, may be enhanced to counteract the vasoconstrictive effects of the activated neurohormones in the presence of anemia. Consistent with this hypothesis, studies have shown that a variety of vasoconstrictive neurohormones, including norepinephrine and angiotensin II, directly stimulate the production of natriuretic peptides. 5 In the present study, however, use of -blockers, angiotensin-converting enzyme inhibitors (ACEI), or angiotensin-receptor blockers (ARB) was not associated with decreased levels of natriuretic peptides in 63 anemic patients (39 on -blockers, ACEI, or ARB). Anemic patients taking -blockers, ACEI, or ARB were more likely than those taking none of these medications to have hypertension and a history of coronary revascularization, to have lower glomerular filtration rate and cardiac index, and to be prescribed diuretics and statins. After adjustment for these differences, there were no significant differences in natriuretic peptide levels between patients taking and those not taking -blockers, ACEI, or ARB (adjusted mean ± SE, 160.4±39.8 and 142.4±54.0 pg/ml for BNP, 68.7±14.4 and 38.1±19.6 pg/ml for ANP, p>0.1 for both). Nevertheless, given the cross-sectional nature of the present study, prospective studies are warranted to examine the effect of neurohumoral blockade on natriuretic peptide levels in anemic patients.
Another possible mechanism underlying the association between anemia and elevated natriuretic peptide levels is downregulation of natriuretic peptide clearance receptors adapted to hypoxia. Reduced serum Hb levels decrease the oxygen-carrying capacity of the blood. 20 An experimental study reported that exposure of rats to short-term (48 h) and chronic (4 week) hypoxia decreased ANP-clearance-receptor gene expression in the pulmonary vasculature bed, the major site of receptor-mediated ANP clearance. 27 Thus, hypoxia caused by anemia may contribute to elevated plasma levels of natriuretic peptides by decreasing the clearance of natriuretic peptides in anemic patients.
Strengths and Limitations
The strength of the present study is that the LV hemodynamic variables were obtained by the use of a micromanometer catheter not a fluid-filled catheter. Although a fluid-filled catheter accurately measures venous pressures, late diastolic LV pressures, and aortic pressures, it can not accurately determine rapidly changing pressures as occur during LV isovolumetric contraction and relaxation. 28 Use of a micromanometer catheter enabled us to determine the negative dP/dt and the time constant of LV relaxation ( ), indices of LV relaxation, and we have shown that the association of anemia with elevated BNP levels is independent of impaired LV relaxation, a strong determinant of elevated BNP levels. 21 There are several limitations to the present study. First, we do not have complete data on LV mass or left atrial volume, which could have influenced our results. [29] [30] [31] However, earlier studies have shown that the association between anemia and elevated BNP levels is independent of LV hypertrophy. 19 Second, our study group was composed largely of elderly patients with and at an increased risk for CAD, so our findings can not be extended to other populations.
Clinical Implications
Studies have reported the usefulness of the measurement of natriuretic peptide levels, particularly BNP, for the diagnosis of HF 3 and detection of preclinical LV dysfunction. 4 We and others, 17, 31, 32 however, have shown that elevated BNP levels are not specific for HF or LV dysfunction, but are also associated with many noncardiac factors including anemia, female gender, and lower body mass index. Thus, these confounders need to be considered when interpreting BNP measurements for the diagnosis of HF or detection of LV dysfunction.
Given that anemia and elevated BNP levels are both predictive of adverse prognosis in various populations, the association between anemia and elevated BNP levels may be of clinical importance. Elevated BNP levels are associated with adverse prognosis in patients with HF 6-8 and those with CAD 9,10 and even in the general population. 11 Anemia also is a powerful predictor for adverse cardiovascular outcomes in these populations. [12] [13] [14] [15] Importantly, van der Meer et al reported that the prognostic value of elevated BNP levels disappeared after adjustment for anemia in patients with stable, mild-to-advanced chronic HF. 33 In contrast, Ralli et al reported that elevated BNP levels provided incremental prognostic value to anemia in patients with advanced HF referred for HF management and heart transplantation evaluation. 34 Further studies are necessary to examine whether the prognostic association of elevated BNP levels is mediated by anemia or each adversely affects prognosis in additional ways not only in patients with HF, but also in other populations.
